Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Deffered Revenue: 2015-2025

Historic Non-Current Deffered Revenue for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $12.5 million.

  • Intellia Therapeutics' Non-Current Deffered Revenue fell 44.53% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 44.53%. This contributed to the annual value of $18.3 million for FY2024, which is 53.01% down from last year.
  • Intellia Therapeutics' Non-Current Deffered Revenue amounted to $12.5 million in Q3 2025, which was down 0.00% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Non-Current Deffered Revenue ranged from a high of $63.5 million in Q4 2021 and a low of $12.5 million during Q2 2025.
  • For the 3-year period, Intellia Therapeutics' Non-Current Deffered Revenue averaged around $19.9 million, with its median value being $13.9 million (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Non-Current Deffered Revenue surged by 251.99% in 2021, and later crashed by 71.99% in 2023.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Non-Current Deffered Revenue stood at $63.5 million in 2021, then slumped by 68.60% to $19.9 million in 2022, then spiked by 94.93% to $38.9 million in 2023, then plummeted by 53.01% to $18.3 million in 2024, then crashed by 44.53% to $12.5 million in 2025.
  • Its last three reported values are $12.5 million in Q3 2025, $12.5 million for Q2 2025, and $13.2 million during Q1 2025.